SBC Medical Group Holdings Inc. - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. SBC Medical Group Holdings Inc. (SBC) is a management company headquartered in Irvine, California, and Tokyo, Japan, providing comprehensive management services to cosmetic treatment centers, primarily in Japan. The company operates as a single reporting segment and is classified as an emerging growth company and a smaller reporting company.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues, Net | $43,060,562 | $47,328,701 |
| Gross Profit | $30,346,734 | $37,733,084 |
| Gross Margin | 70.47% | 79.73% |
| Net Income (Attributable to SBC) | $11,308,071 | $21,502,446 |
| Operating Cash Flow | $9,231,938 | $1,928,621 |
| Cash and Cash Equivalents (End of Period) | $167,305,095 | $132,055,823 |
| Total Debt (Bank & Other Borrowings) | $40,435,018 | $42,833,484 |
| Working Capital | $176,212,567 | N/A |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by 9.02% ($4.27 million) year-over-year. This was driven by a 42.16% drop in franchising revenue due to a fee structure revision effective April 2025 and a 39.08% decline in rental services revenue. These decreases were partially offset by a 36.68% increase in management services revenue and a 115.22% increase in "Other" revenue.
- Profitability Impact: Net income attributable to SBC decreased by 47.41% ($10.19 million). A significant factor was the absence of an $8.75 million one-time gain on the redemption of life insurance policies recorded in Q1 2025.
- Foreign Exchange: The depreciation of the Japanese Yen against the U.S. Dollar negatively impacted reported revenues by approximately $1.23 million and net income by $324,425.
- Operating Expenses: Operating expenses decreased by 6.68% ($904,291), primarily due to reductions in office, utility, and other expenses, as well as depreciation.
Guidance, Outlook, Risks, and Unusual Items
- Subsequent Event: In April 2026, the Company completed a secondary public offering of 3,565,000 shares at $3.25 per share. All shares were sold by the CEO; the Company received no proceeds but incurred approximately $1.4 million in transaction costs.
- Investment Commitment: The Company has committed to an additional $5 million cash investment in OT Midco Holdings, LLC, payable in December 2026.
- Legal Proceedings: A purported stockholder class action complaint was filed in February 2026 in the Court of Chancery of Delaware regarding the Company's charter provisions on director removal. The Company cannot estimate the potential loss.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of March 31, 2026, due to previously identified material weaknesses in internal control over financial reporting that remained un-remediated.
- Related Party Transactions: A significant portion of revenue (approx. 88%) and accounts receivable are derived from related parties (Medical Corporations where CEO relatives are members).
Investor Verification Checklist
- Related Party Concentration: Verify the sustainability of revenue streams given that nearly 90% of revenue comes from related parties (Medical Corporations) and the top three customers represent over 60% of total revenue.
- Internal Control Remediation: Review the specific remediation plan for the material weaknesses in internal controls over financial reporting and the timeline for their resolution.
- FX Sensitivity: Assess the impact of continued Japanese Yen volatility on future earnings, as the majority of operations are in Japan while reporting is in USD.
- Fee Structure Impact: Monitor the long-term effects of the April 2025 fee structure revision on franchising and management service revenues.
- Legal Exposure: Track the status of the Delaware class action lawsuit regarding director removal provisions.